A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 31 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 25 Feb 2014 New trial record